Shuttle Pharmaceuticals Holdings, Inc. (SHPH), a specialty pharmaceutical company, on Tuesday announced it has reached 25% enrollment in the initial randomized portion of its Phase 2 clinical trial evaluating Ropidoxuridine or IPdR for the treatment of glioblastoma.
The trial is designed to determine the optimal dose of Ropidoxuridine in combination with radiation therapy for patients with the most aggressive form of brain cancer, IDH wild-type, methylation negative glioblastoma.
The trial aims to improve survival outcomes for patients who currently have limited treatment options, with radiation being the standard of care.
This Phase 2 study will initially randomize 40 patients into two groups (1,200 mg/day and 960 mg/day) to identify the optimal dose before enrolling additional patients. The study is conducted at leading cancer centers, including Georgetown University Medical Center, UNC Medical Center, and John Theurer Cancer Center.
Shuttle Pharma previously received Orphan Drug Designation from the FDA for Ropidoxuridine in glioblastoma treatment, providing potential marketing exclusivity upon approval.
The company is on track to complete enrollment in the coming months, with results expected to drive future clinical development for glioblastoma.
Currently, SHPH is trading at $0.86 down by 2.69%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.